Literature DB >> 8251915

The role of myc in transformation by BCR-ABL.

C L Sawyers1.   

Abstract

The BCR-ABL gene plays a central role in the pathogenesis of chronic myelogenous leukemia. Despite a detailed understanding of the regions of BCR and ABL required for transformation by BCR-ABL, little is known about the signalling pathway by which BCR-ABL causes transformation. The nuclear oncogene c-myc plays a critical role in BCR-ABL transformation. Levels of c-myc RNA are high in cells transformed by BCR-ABL, and overexpression of dominant negative forms of myc blocks transformation by BCR-ABL. These findings suggest that myc may be a useful therapeutic target in BCR-ABL-related leukemias.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8251915     DOI: 10.3109/10428199309047862

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  10 in total

1.  Affinity-based proteomics reveal cancer-specific networks coordinated by Hsp90.

Authors:  Kamalika Moulick; James H Ahn; Hongliang Zong; Anna Rodina; Leandro Cerchietti; Erica M Gomes DaGama; Eloisi Caldas-Lopes; Kristin Beebe; Fabiana Perna; Katerina Hatzi; Ly P Vu; Xinyang Zhao; Danuta Zatorska; Tony Taldone; Peter Smith-Jones; Mary Alpaugh; Steven S Gross; Nagavarakishore Pillarsetty; Thomas Ku; Jason S Lewis; Steven M Larson; Ross Levine; Hediye Erdjument-Bromage; Monica L Guzman; Stephen D Nimer; Ari Melnick; Len Neckers; Gabriela Chiosis
Journal:  Nat Chem Biol       Date:  2011-09-25       Impact factor: 15.040

2.  A MAPK/HNRPK pathway controls BCR/ABL oncogenic potential by regulating MYC mRNA translation.

Authors:  Mario Notari; Paolo Neviani; Ramasamy Santhanam; Bradley W Blaser; Ji-Suk Chang; Annamaria Galietta; Anne E Willis; Denis C Roy; Michael A Caligiuri; Guido Marcucci; Danilo Perrotti
Journal:  Blood       Date:  2005-11-17       Impact factor: 22.113

3.  Bcr is a negative regulator of the Wnt signalling pathway.

Authors:  Angelika Ress; Karin Moelling
Journal:  EMBO Rep       Date:  2005-10-07       Impact factor: 8.807

4.  Inhibition of the Raf-1 kinase by cyclic AMP agonists causes apoptosis of v-abl-transformed cells.

Authors:  E M Weissinger; G Eissner; C Grammer; S Fackler; B Haefner; L S Yoon; K S Lu; A Bazarov; J M Sedivy; H Mischak; W Kolch
Journal:  Mol Cell Biol       Date:  1997-06       Impact factor: 4.272

5.  A screening-based approach to circumvent tumor microenvironment-driven intrinsic resistance to BCR-ABL+ inhibitors in Ph+ acute lymphoblastic leukemia.

Authors:  Harpreet Singh; Anang A Shelat; Amandeep Singh; Nidal Boulos; Richard T Williams; R Kiplin Guy
Journal:  J Biomol Screen       Date:  2013-08-29

6.  Loss of the xeroderma pigmentosum group B protein binding site impairs p210 BCR/ABL1 leukemogenic activity.

Authors:  N L Pannucci; D Li; S Sahay; E K Thomas; R Chen; I Tala; T Hu; B T Ciccarelli; N J Megjugorac; H C Adams Iii; P L Rodriguez; E R Fitzpatrick; D Lagunoff; D A Williams; I P Whitehead
Journal:  Blood Cancer J       Date:  2013-08-16       Impact factor: 11.037

Review 7.  The Philadelphia chromosome in leukemogenesis.

Authors:  Zhi-Jie Kang; Yu-Fei Liu; Ling-Zhi Xu; Zi-Jie Long; Dan Huang; Ya Yang; Bing Liu; Jiu-Xing Feng; Yu-Jia Pan; Jin-Song Yan; Quentin Liu
Journal:  Chin J Cancer       Date:  2016-05-27

8.  Lineage-Specific Genes Are Prominent DNA Damage Hotspots during Leukemic Transformation of B Cell Precursors.

Authors:  Bryant Boulianne; Mark E Robinson; Philippa C May; Leandro Castellano; Kevin Blighe; Jennifer Thomas; Alistair Reid; Markus Müschen; Jane F Apperley; Justin Stebbing; Niklas Feldhahn
Journal:  Cell Rep       Date:  2017-02-14       Impact factor: 9.423

9.  Activation of protein kinase A (PKA) by 8-Cl-cAMP as a novel approach for antileukaemic therapy.

Authors:  E M Weissinger; K Oettrich; C Evans; H-G Genieser; F Schwede; M Dangers; E Dammann; H-J Kolb; H Mischak; A Ganser; W Kolch
Journal:  Br J Cancer       Date:  2004-07-05       Impact factor: 7.640

Review 10.  The TKI Era in Chronic Leukemias.

Authors:  Danilo De Novellis; Fabiana Cacace; Valeria Caprioli; William G Wierda; Kris M Mahadeo; Francesco Paolo Tambaro
Journal:  Pharmaceutics       Date:  2021-12-20       Impact factor: 6.321

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.